Biodexa Announces 1-for-8 Reverse ADS Split Effective October 26
Summary
Biodexa is implementing a 1-for-8 reverse ADS split effective October 26, 2026, changing the ADS ratio from 1:50 to 1:400 ordinary shares. ADS holders must exchange 8 old ADSs for 1 new ADS; ordinary shares are unaffected.
Key Events · Corporate Governance and Compliance · BDRX
-
1-for-8 Reverse ADS Split Announced
ADS ratio changes from 1 ADS representing 50 ordinary shares to 1 ADS representing 400 ordinary shares, effective on or about October 26, 2026. ADS holders must surrender 8 old ADSs (CUSIP 59564R872) for 1 new ADS (CUSIP 59564R864).
-
Ordinary Shares Unaffected
The ratio change applies only to ADSs; the underlying ordinary shares are not altered. This is a mechanical adjustment to the ADS structure, not a change in share count or ownership.
-
Listing Compliance Context
The reverse ADS split follows the shareholder-approved 1-for-10,000 reverse stock split in July 2026 and comes amid a going concern warning with only £3.23 million in cash as of June 30, 2026. The move appears aimed at maintaining NASDAQ listing requirements.
-
Mandatory Exchange Process
JPMorgan Chase Bank, N.A., as depositary, will contact ADS holders to arrange the mandatory exchange. No fractional ADSs will be allocated; aggregate fractions will be sold and net proceeds distributed to entitled holders.
Analysis · BDRX · Life Sciences
Biodexa is changing its ADS ratio from 1 ADS representing 50 ordinary shares to 1 ADS representing 400 ordinary shares, effective on or about October 26, 2026. This has the same effect as a one-for-eight reverse ADS split for ADS holders, who must surrender 8 old ADSs to receive 1 new ADS. The ordinary shares themselves are unaffected. This move follows the shareholder-approved 1-for-10,000 reverse stock split from July 2026 and comes amid a going concern warning and a cash balance of only £3.23 million as of June 30, 2026. The ratio change is likely aimed at boosting the ADS price to maintain NASDAQ listing compliance, but it does not change the company's underlying financial position or the substantial dilution risk from its ongoing warrant and resale programs.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.7% of the 1731 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $360.4K. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.